Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04885361
Previous Study | Return to List | Next Study

To Evaluate the Safety, and Immunogenicity of Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT 3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04885361
Recruitment Status : Recruiting
First Posted : May 13, 2021
Last Update Posted : June 9, 2021
Sponsor:
Information provided by (Responsible Party):
OSE Immunotherapeutics

Brief Summary:

The proposed study is a phase 1 study which will evaluate the safety, reactogenicity and immunogenicity of two doses regimen of CoVepiT vaccine (OSE-13E) in the population of n=48 healthy volunteers 18 to 45 (inclusive) years old, vaccinated or not by authorized COVID-19 vaccine.

Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.

First 4 subjects will serve as sentinel cohort and 7 days reactogenicity data of these subjects will be reviewed by the independent safety monitoring committee (SMC) before proceeding to the vaccination of remaining volunteers. The progress of the study will be overviewed by a safety monitoring committee (SMC).

The CoVepiT vaccine is a peptide-based vaccine aiming to induce CD8+T-cell-mediated immune response against 11 different proteins of SARS-CoV-2 virus.


Condition or disease Intervention/treatment Phase
Coronavirus Disease (COVID-19) Biological: CoVepiT (OSE13E) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Open Label, Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of OSE-13E, a Multiepitope-based Vaccine Candidate Against COVID-19, in Healthy Adults (COVEPIT-3)
Actual Study Start Date : May 26, 2021
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : March 31, 2022

Arm Intervention/treatment
Experimental: Arm 1 injection
The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
Biological: CoVepiT (OSE13E)
Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.

Experimental: Arm 2 injections separated by 21 days
The dose of 1 ml will be administered subcutaneously, preferably into deltoid region of the non-dominant arm.
Biological: CoVepiT (OSE13E)
Study will be open label and will be randomized 1:1 in two parallel study arms receiving either one single dose or two doses separated by 21 days.




Primary Outcome Measures :
  1. The incidence of solicited local reactogenicity signs and symptoms [ Time Frame: up to 7 days after each injection ]
  2. The incidence of solicited systemic reactogenicity signs and symptoms [ Time Frame: up to 7 days after each injection ]
  3. The incidence of unsolicited adverse events in study participants. [ Time Frame: up to 28 days after each vaccination. ]
  4. The occurrence of serious adverse events (SAE). [ Time Frame: throughout study completion, an average of 6 months. ]
  5. The occurrence of adverse events of special interest (AESI), including potentially immune mediated disorders (pIMD) [ Time Frame: throughout study completion, an average of 6 months. ]
  6. Proportion of subjects with significantly increased CD8+ T cells responding to SARS-CoV-2 wild type epitopes at Week 6 - 1 versus 2 doses [ Time Frame: Week 6 ]

Secondary Outcome Measures :
  1. Proportion of subjects with significantly increased CD8+ T cells responding to SARS-CoV-2 wild type epitopes [ Time Frame: Day 22, Month 3 and Month 6 ]
  2. Geometric mean fold rise of CD8+ T cells responding to SARS-CoV-2 wild type [ Time Frame: Day 22, Month 3 and Month 6 ]
  3. Proportion of participants achieving ≥2-fold rise of secreting spots specific to SARS-CoV-2 wild type epitopes [ Time Frame: At baseline and after each vaccination ]
  4. Change in geometric mean count (GMC) of CD8+ T cells antigen specific to SARS-CoV-2 wild type epitopes [ Time Frame: from the pre-injection baseline (Day 1) to Day 22, Week 6, Month 3 and Month 6 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subject's meeting all the following criteria are eligible to participate in this study:

  • Males or females 18 to 45 (inclusive) years of age, at screening.
  • Healthy participants as determined based on medical history, clinical laboratory results, vital sign measurements, and physical examination at screening.
  • Subjects not previously vaccinated with any COVID-19 vaccine OR Subjects who have completed the vaccination according to an officially accepted scheme (e.g., healthcare workers), at least 4 weeks prior to enrollment, with an authorized vaccine which induces neutralizing antibodies against the SARS-CoV-2 Spike protein.
  • Willing and able to give informed consent.
  • Willing to accept following contraceptive measures:

Exclusion Criteria:

  • Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care, inclusive of changes in medication in the past 2 months (at the discretion of the investigator). This includes any current workup of undiagnosed illness that could lead to a new condition, including but not limited to any of the following conditions that are risk factors of severe illness from the virus that causes COVID-19:

    • Active cancer (malignancy) within 5 years prior to first study vaccination (with the exception of adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
    • Chronic kidney disease
    • COPD
    • Moderate to severe asthma
    • Current tobacco smoking
    • People who have had an organ transplant.
    • Heart conditions, such as heart failure, coronary artery disease, or cardiomyopathies
    • BMI ≥ 30 kg/m2 or BMI <17 kg/m2
    • Type 2 diabetes mellitus
    • Chronic liver disease
    • Sickle cell disease Hypertension
  • Type 1 diabetes
  • Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
  • Participation in research involving an investigational product (drug/biologic/device) within 45 days prior to first study vaccination.
  • History of a confirmed diagnosis of SARS, MERS or COVID-19 disease (confirmed by a specific test for each disease) or known exposure during 2-4 weeks prior to enrollment to a SARS-CoV-2 positive confirmed close contact (eg, family member, housemate, daycare provider, aged parent requiring care), at the discretion of the investigator.
  • Professionals involved in direct care of the COVID-19 patients and with a high risk of exposure to SARS-CoV-2 (i.e., healthcare worker of intensive care unit at infectology department ).
  • Currently taking any product (investigational or off-label) for prevention of COVID-19 disease.
  • Positive rapid test for SARS-CoV-2 (ELISA or PCR) at screening or prior to first vaccination.
  • Received influenza vaccination within 14 days prior to first study vaccination, or any other vaccine within 4 weeks prior to first study vaccination. NOTE: COVID-19 marketed vaccines may be allowed as long inclusion criterion #3 is met.
  • Any autoimmune or immunodeficiency disease/condition (iatrogenic or congenital).
  • Chronic administration (defined as more than 14 continuous days) of immunosuppressant, systemic glucocorticosteroids, or other immune-modifying drugs within 4 months prior to first study vaccination or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Any acute illness concurrent or within 14 days prior to first study vaccination (medical history and/or physical examination) or documented temperature of ≥38°C during this period. This includes respiratory or constitutional symptoms consistent with SARS-CoV-2 (COVID-19) (ie, cough, sore throat, difficulty breathing)
  • Known disturbance of coagulation (iatrogenic or congenital). NOTE: The use of ≤325 mg of aspirin per day as prophylaxis is permitted, but the use of other platelet aggregation inhibitors, thrombin inhibitors, Factor Xa inhibitors, or warfarin derivatives is exclusionary, regardless of bleeding history, because these imply treatment or prophylaxis of known cardiac or vascular disease.
  • Any neurological disease or history of significant neurological disorder (eg, meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré syndrome [genetic/congenital or acquired]).
  • Vital sign (blood pressure, pulse, temperature) abnormalities of toxicity grade >1
  • Clinical laboratory abnormalities of toxicity grade >1 for selected serum chemistry and hematology parameters
  • Any known allergies to products contained in the investigational product or latex allergy, or history of severe allergic reaction (e.g., swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
  • Women who are pregnant, breastfeeding or who plan to become pregnant during the study.
  • History of alcohol abuse or drug addiction within one year prior to the first study vaccination.
  • Any condition that, in the opinion of the investigator, would pose a health risk to the subject if enrolled or could interfere with evaluation of the study vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting).
  • Study team member or first-degree relative of any study team member (inclusive of sponsor or delegate, and site personnel involved in the study).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04885361


Contacts
Layout table for location contacts
Contact: Ose immunotherapeutics 01 43 29 78 57 contact@ose-immuno.com

Locations
Layout table for location information
Belgium
Center for Vaccinology (CEVAC), Recruiting
Gent, Belgium
Sponsors and Collaborators
OSE Immunotherapeutics
Layout table for additonal information
Responsible Party: OSE Immunotherapeutics
ClinicalTrials.gov Identifier: NCT04885361    
Other Study ID Numbers: OSE-13E-C102
First Posted: May 13, 2021    Key Record Dates
Last Update Posted: June 9, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases